Pasithea Therapeutics Corp. (KTTA)
KTTANASDAQ-CMBiotechnology: Pharmaceutical Preparations
$0.5300
-0.0123 (-2.27%) today
Regular session, Nov 10, 3:14 PM ET
- Market cap
- $17.71m
- P/E
- –
- EPS, last 4 quarters
- $-1.58
- Dividend yield
- –
- Day range
- $0.5100 to $0.5500
- 52-week range
- $0.2810 to $2.06
- Average volume
- 711.8k
- Previous close
- $0.5423
Analysts
1 coveringBuy1 buy, 0 hold, 0 sell
Targets a year out average $3.00, +466.0% from here
Earnings
next estimate $-0.2100Next report Nov 12, 2026
Sep 2025
–
Dec 2025
-394.4%
Mar 2026
+73.3%
Jun 2026
0.0%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$3.11m | -$10.26m | -$4.88m | -$5.71m |
| Net income | -$3.04m | -$10.11m | -$2.87m | -$5.27m |
News
8 latest- FDA Clears Pasithea's PAS-004 IND For Phase 2 Study In NF1-Related Skin Tumors; Stock Up RTTNews · Nov 3, 2026
- New Strong Buy Stocks for July 20thZacks · Jul 20, 2026
- Pasithea Therapeutics (KTTA) Could Find a Support Soon, Here's Why You Should Buy the Stock NowZacks · Jun 10, 2026
- Pasithea's PAS-004 Receives FDA Orphan Drug Designation In Treating AL. Sclerosis RTTNews · Jun 2, 2026
- Pasithea Therapeutics' PAS-004 Receives FDA Orphan Drug Designation For ALS RTTNews · Jun 2, 2026
- Pasithea Therapeutics Appoints Kartik Krishnan As CMO RTTNews · May 4, 2026
- Pasithea Wins FDA Rare Pediatric Disease Status For PAS-004 To Treat Neurofibromatosis Type 1 RTTNews · Apr 20, 2026
- Pasithea Therapeutics (KTTA) Price Target Increased by 50.00% to 3.06Fintel · Dec 20, 2025
The company
Pasithea is a clinical-stage biotechnology company primarily focused on the research and development of its lead drug candidate, PAS-004, a next-generation macrocyclic MEK inhibitor intended for the treatment of RASopathies, MAPK pathway-driven tumors, and other diseases. The Company is currently testing PAS-004 in a Phase 1 clinical trial in advanced cancer patients ( NCT06299839 ), and a Phase 1/1b clinical trial in adult patients with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas ( NCT06961565 ).
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- pasithea.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.